For Research Purposes Only

PurePeptideHub
weight-lossapproved

Semaglutide

Semaglutide (Ozempic/Wegovy)

Overview

A GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). One of the most studied and widely used peptides.

Mechanism of Action

Mimics the GLP-1 hormone, which regulates appetite and food intake. Slows gastric emptying, increases insulin secretion, and acts on brain regions controlling hunger.

Popular Research Uses

  • Weight loss
  • Blood sugar control
  • Appetite suppression
  • Type 2 diabetes management
  • Cardiovascular risk reduction

Potential Side Effects

  • Nausea and vomiting
  • Diarrhea or constipation
  • Abdominal pain
  • Fatigue
  • Injection site reactions

Warnings

  • Requires prescription
  • GI side effects are common
  • Contraindicated with history of medullary thyroid carcinoma
  • May cause pancreatitis
  • Muscle loss concerns without exercise

Dosage Information

Dose is gradually increased over weeks to minimize side effects.

Research Sources

Disclaimer: This content is for research and educational purposes only. Semaglutide is not approved for human consumption. Always consult with qualified healthcare professionals before making any decisions related to peptide research.